A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States

Abstract

INTRODUCTION: Inflammatory bowel diseases (IBD) affect >3 million Americans and are associated with tremendous economic burden. Direct patient-level financial impacts, financial distress, and financial toxicity are less well understood. We aimed to summarize the literature on patient-level financial burden, distress, and toxicity associated with IBD in the United States. METHODS:We conducted a literature search of US studies from 2002 to 2022 focused on direct/indirect costs, financial distress, and toxicity for patients with IBD. We abstracted study objectives, design, population characteristics, setting, and results.

Utilizing a multisystemic model of resilience to synthesize research in youth with inflammatory bowel disease: a narrative review

“…ability to afford out of pocket costs, access to health insurance, being able to have transportation to medical visits, ability to take off work to attend medical appointments, etc.) have demonstrated that, despite limited research, costs of having IBD are high, which is impactful for families and provides a salient context of risk to be considered ( 47 , 48 ).…”

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management

“…The prevalence of inflammatory bowel disease (IBD) is increasing in most countries and is reaching 1% in high‐incidence areas 1 . This not only increases the economic burden of IBD care but also places additional strains on healthcare professionals taking care of IBD patients 2 . This has naturally led to a gradual shift of conventional medical management tasks from physicians to highly specialised IBD nurses 3 .…”